Phenylpropanolamine OROS (Acutrim) vs. placebo in combination with caloric restriction and physician‐managed behavior modification

Michael Weintraub, Gerald Ginsberg, E. Carol Stein, P. R. Sundaresan, Barbara Schuster, Patrick O'Connor, Louise M. Byrne

Research output: Contribution to journalArticlepeer-review

7 Scopus citations


We added phenylpropanolamine OROS (Acutrim; Ciba‐Geigy Corp.) or placebo to a physician‐managed behavior modification, mild caloric restriction, and exercise weight control program. One hundred six healthy, overweight (115% to 130% ideal body weight) women participated in this 14‐week double‐blind clinical trial. On average, the participants who took Acutrim lost significantly more weight (X̄ ± SE; 6.1 ± 0.6 kg; 8.0% ± 0.8%) than did those taking placebo (4.3 ± 0.7 kg; 5.5% ± 0.8%; P < 0.05). Those taking Acutrim continued to lose weight over the Christmas holiday, while the placebo group gained weight. Fifteen participants taking placebo withdrew, three because of adverse drug reactions (ADRs). Thirteen of 53 participants in the Acutrim group left the study, two because of ADRs. Dry mouth was the most frequent complaint from participants taking Acutrim. No serious cardiovascular effects occurred. Both complaints and the number of participants reporting ADRs decreased with continued dosing. We conclude that Acutrim is a safe, modestly effective adjunct to a physician‐managed, integrated weight control program. Clinical Pharmacology and Therapeutics (1986) 39, 501–509; doi:

Original languageEnglish (US)
Pages (from-to)501-509
Number of pages9
JournalClinical Pharmacology & Therapeutics
Issue number5
StatePublished - May 1986

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'Phenylpropanolamine OROS (Acutrim) vs. placebo in combination with caloric restriction and physician‐managed behavior modification'. Together they form a unique fingerprint.

Cite this